Table 1.
Correlations between CCDC45 expression and the clinicopathological features of HCC patients.
| Characteristics | n | CCDC45 expression | P value | |
|---|---|---|---|---|
| Low | High | |||
| Age (years) | ||||
| >50 | 50 | 25 (50.00%) | 25 (50.00%) | 1.000 |
| ≤50 | 40 | 20 (50.00%) | 20 (50.00%) | |
| Gender | ||||
| Male | 80 | 39 (48.75%) | 41 (51.25%) | 0.502 |
| Female | 10 | 6 (60.00%) | 4 (40.00%) | |
| AJCC stage | ||||
| I | 52 | 30 (57.69%) | 22 (42.31%) | 0.088 |
| II-III | 38 | 15 (39.47%) | 23 (60.53%) | |
| HBsAg | ||||
| Negative | 19 | 9 (47.37%) | 10 (52.63%) | 0.796 |
| Positive | 71 | 36 (50.70%) | 35 (49.30%) | |
| AFP (μg/L) | ||||
| >400 | 33 | 15 (45.45%) | 18 (54.55%) | 0.512 |
| ≤400 | 57 | 30 (52.63%) | 27 (47.37%) | |
| Total bilirubin (μmol/L) | ||||
| >20 | 15 | 8 (53.33%) | 7 (46.67%) | 0.777 |
| ≤20 | 75 | 37 (49.33%) | 38 (50.67%) | |
| ALT (U/L) | ||||
| >45 | 31 | 16 (51.61%) | 15 (48.39%) | 0.824 |
| ≤45 | 59 | 29 (49.15%) | 30 (50.85%) | |
| GGT (U/L) | ||||
| > 40 | 59 | 28 (47.46%) | 31 (52.54%) | 0.506 |
| ≤40 | 31 | 17 (54.84%) | 14 (45.16%) | |
| Edmondson-Steiner grade | ||||
| I-II | 53 | 32 (60.38%) | 21 (39.62%) | 0.018 |
| III-IV | 37 | 13 (35.14%) | 24 (64.86%) | |
| Tumor number | ||||
| Single | 79 | 41 (51.90%) | 38 (48.10%) | 0.522 |
| Multiple | 11 | 4 (36.36%) | 7 (63.64%) | |
| Tumor size (cm) | ||||
| > 5 | 28 | 11 (39.29%) | 17 (60.71%) | 0.172 |
| ≤5 | 62 | 34 (53.84%) | 28 (46.16%) | |